ClinicalTrials.gg
Not yet recruitingNCT07864506Updated Oct 7, 2026

Testing the Effects of Temperature & Humidity on Children With and Without Asthma in an Environmental Climatic Chamber

An interventional study of Controlled Temperature and Humidity Exposure in Asthma, sponsored by University of Ontario Institute of Technology. Not yet recruiting at 1 site in Canada. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Ontario Institute of Technology · Not applicable, Interventional, and Basic science

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
11 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Asthma with a site in Canada — 42 open to participants now, 57 under way, 11 of them phase 3. Asthma · Canada.

Planned enrollment
215th of 367
60 · median 110
Started
2026
with 12 others
No phase
85 of 429
14 open now
Primary completion
2027-09
later than 35 of 56 live
Registered
428th of 429
by date

Among the 429 studies in Asthma with a site in Canada, this one is the 215th largest by planned enrollment of the 367 interventional ones that give a count, is one of 13 that started in 2026, is one of 85 with no phase, reaches primary completion later than 35 of the 56 other live ones, and was the 428th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

42 of the 429 studies in Asthma with a site in Canada are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 11 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Asthma with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn how different temperature and humidity conditions affect breathing, lung function, exercise capacity, symptoms, and other physical responses in children and youth aged 11 to 18 years with asthma, compared with age- and sex-matched children and youth without asthma.

The main questions it aims to answer are:

  • How do different temperature and humidity conditions affect lung function, breathing symptoms, exercise capacity, and physiological responses in children and youth with asthma?
  • Do children and youth with asthma respond differently to these environmental conditions than children and youth without asthma?
  • Do sex and gender influence these responses?

Researchers will compare children and youth with asthma to age- and sex-matched children and youth without asthma to see if temperature and humidity exposures have different effects on breathing, exercise performance, symptoms, and physiological responses.

Participants will:

  • Attend two study visits in a climate-controlled chamber.
  • Be exposed to hot, cold, and varying humidity conditions for short periods of time.
  • Complete breathing tests and exercise testing before, during, and after each exposure.
  • Have symptoms, physical activity, and physiological responses monitored throughout the study.
03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • children
  • lungs
  • environmental conditions
  • adolescents
  • temperature
  • spirometry
  • lung function
  • weather
  • humidity
  • respiratory
04

Who can participate

Ages eligible
11 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and youth aged 11 to 18 years
  • Able to provide assent/consent, with parent or guardian consent when required
  • Diagnosed with asthma and currently stable (for the asthma group)
  • Willing to attend study visits at the ACE research facility in Oshawa, Ontario
  • For the control group: No asthma or other respiratory condition

Exclusion criteria

Exclusion Criteria:

  • Does not meet all inclusion criteria
  • Parent or guardian does not provide consent when required
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Asthma Arm

    Children and youth aged 11 to 18 years with asthma will be exposed to five controlled temperature and humidity conditions (ideal, cold dry, cold humid, hot dry, and hot humid) in a climatic chamber. Lung function, breathing symptoms, exercise capacity, and physiological responses will be measured before, during, and after each exposure.

    Other: Controlled Temperature and Humidity Exposure

  • Active comparator
    Non-asthma Control Arm

    Age- and sex-matched children and youth without asthma will undergo the same environmental exposures and assessments as the asthma group to allow comparison of responses between groups.

    Other: Controlled Temperature and Humidity Exposure

Interventions

  • OtherControlled Temperature and Humidity Exposure

    Exposure to five controlled environmental conditions in a climatic chamber: ideal (18°C, 50-60% RH), cold dry (-15°C, 30-40% RH), cold humid (-15°C, 95-100% RH), hot dry (+35°C, 30-40% RH), and hot humid (+35°C, 95-100% RH). Participants undergo lung function testing, exercise testing, symptom assessments, and physiological monitoring during and after exposures.

06

What researchers measure

Primary outcomes

  1. Change in Lung Function as Measured by Forced Expiratory Volume in 1 Second (FEV1)

    Spirometry will be performed using the In2itive™ (Vitalograph, UK) to assess lung function. FEV1 in mL will be used to evaluate the effects of different temperature and humidity exposures.

    Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.

  2. Change in Forced Vital Capacity (FVC)

    FVC in mL will be measured using the In2itive™ (Vitalograph, UK) to assess lung function.

    Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.

Secondary outcomes

  1. Change in Peak Expiratory Flow (PEF)

    PEF in L/min will be measured using the In2itive™ (Vitalograph, UK) to assess lung function.

    Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.

  2. Change in FEV1/FVC Ratio

    The FEV1/FVC ratio (%) will be calculated from spirometry measurements using the In2itive™ (Vitalograph, UK) to assess airflow limitation.

    Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.

  3. Airway inflammation

    Fractional exhaled nitric oxide (FeNO) will be measured using the NIOX VERO device as a non-invasive biomarker of airway inflammation, measured in parts per billion (ppb).

    Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.

  4. Heart Rate

    Heart rate will be continuously measured using the Zephyr BioHarness and Athena physiological measurement system. Heart rate will be reported in beats per minute (bpm).

    Time frame: Continuously monitored beginning prior to chamber entry and throughout each temperature and humidity exposure condition, including pre-, during, and post-mCAFT. Conditions are separated by a 45-minute washout and repeated across 2 study visits.

  5. Respiratory Rate

    Respiratory rate will be continuously measured using the Zephyr BioHarness and Athena physiological system. Respiratory rate will be reported in breaths per minute.

    Time frame: Continuously monitored beginning immediately prior to chamber entry and throughout each temperature and humidity exposure condition, including the washout periods. Conditions are separated by a 45-minute washout and repeated across 2 study visits.

  6. Heart Rate Variability (HRV)

    HRV in milliseconds will be continuously measured using the Zephyr BioHarness and Athena platform to assess responses to temperature and humidity exposures.

    Time frame: Continuously monitored beginning immediately prior to chamber entry and throughout each temperature and humidity exposure condition, including the washout periods. Conditions are separated by a 45-minute washout and repeated across 2 study visits.

  7. Skin Temperature

    Skin temperature will be continuously measured using the Zephyr BioHarness and Athena physiological measurement platform. Skin temperature will be reported in degree Celsius.

    Time frame: Continuously monitored beginning immediately prior to chamber entry and throughout each temperature and humidity exposure condition, including the washout periods. Conditions are separated by a 45-minute washout and repeated across 2 study visits.

  8. Dyspnea

    Dyspnea will be assessed using the Modified Borg Scale (no units).

    Time frame: Measured 1-5 minutes before entering the chamber, immediately after chamber entry, 1-5 minutes before/after the mCAFT, and after each temperature and humidity exposure. Conditions are separated by a 45-minute washout and repeated across 2 study visits.

  9. Blood Pressure

    Blood pressure will be measured before and after the modified Canadian Aerobic Fitness Test using a blood pressure monitor. Blood pressure will be reported in mmHg.

    Time frame: Measured at the beginning and end of each study visit and within 1-5 minutes before and after mCAFT during each temperature and humidity exposure. Conditions are separated by a 45-minute washout and repeated across 2 study visits.

  10. Peripheral oxygen saturation (SpO2)

    SpO2 will be measured using a fingertip pulse oximeter (Masimo MightySat or Rad-G).

    Time frame: Measured during mCAFT within each temperature and humidity exposure condition. Conditions are separated by a 45-minute washout and repeated across 2 study visits.

  11. Rate of Perceived Exertion (RPE)

    RPE will be assessed using Borg 6-20 scale. RPE will be reported as a score from 6-20.

    Time frame: Assessed 1- 5 minutes before and 1- 5 minutes after mCAFT testing. Conditions are separated by a 45-minute washout and repeated across 2 study visits.

  12. Change in Estimated Peak Oxygen Uptake (VO₂peak) as Measured by the Modified Canadian Aerobic Fitness Test (mCAFT)

    The Modified Canadian Aerobic Fitness Test (mCAFT) will be used to measure exercise capacity. It is a progressive submaximal step test used to estimate peak oxygen uptake (VO₂peak). Participants will complete 3-minute stepping stages of increasing intensity, with cadence and step height adjusted according to age and sex. Estimated peak oxygen uptake (VO₂peak) will be calculated and reported in mL/kg/min.

    Time frame: Measured during the mCAFT within each temperature and humidity exposure condition. Assessments are repeated across two study visits approximately 2 weeks apart, with a 45-minute washout between conditions.

  13. Change in Maximum Stage Achieved on the Modified Canadian Aerobic Fitness Test (mCAFT)

    The Modified Canadian Aerobic Fitness Test (mCAFT) will be used to measure exercise capacity. It is a progressive submaximal step test consisting of 3-minute stepping stages of increasing intensity, with cadence and step height adjusted according to age and sex. The maximum stage successfully completed by each participant will be recorded.

    Time frame: Measured during the Modified Canadian Aerobic Fitness Test (mCAFT) within each temperature and humidity exposure condition. Assessments are repeated across two study visits approximately 2 weeks apart, with a 45-minute washout between conditions.

  14. Respiratory Medications Used Prior to Testing

    Respiratory medications used prior to each temperature and humidity exposure condition, including medication name, dose, and time of administration.

    Time frame: Recorded prior to each temperature and humidity exposure condition (ideal, cold-dry, cold-humid, hot-dry, and hot-humid) across 2 study visits.

  15. Exposure Duration

    Duration of completion of each temperature and humidity exposure condition, calculated as time between chamber entry and chamber exit. Measured in minutes.

    Time frame: Measured during each exposure condition (ideal, cold-dry, cold-humid, hot-dry, and hot-humid) across 2 study visits.

  16. Actions Taken in the Chamber

    Actions taken during/after each temperature and humidity exposure condition, including rescue respiratory medication use, cooling chair use, provision of coverings (e.g., blankets), early exit from the chamber, and other exposure-related will be noted down by study staff.

    Time frame: Measured during/after each temperature and humidity exposure condition (ideal, cold-dry, cold-humid, hot-dry, and hot-humid) across 2 study visits.

  17. Participant Age

    Participant age will be collected and reported in years.

    Time frame: Measured once during screening and baseline assessments on Day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  18. Sex at Birth

    Participant reported sex assigned at birth will be collected and reported as categorical options.

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  19. Gender Identity

    Participant reported gender identity will be collected and reported as categorical options.

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  20. Years Since Asthma Diagnosis

    Time since diagnosed asthma will be collected and reported in years.

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  21. Asthma Triggers

    Participant asthma triggers, including allergic and non-allergic triggers, will be collected and reported as categorical options and free text.

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  22. Height

    Participant height will be measured and reported in meters (m).

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  23. Weight

    Participant weight will be measured and reported in kilograms (kg).

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  24. Respiratory Medication Use

    Current respiratory medication use reported as categorical options and free text.

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  25. Body Mass Index (BMI)

    BMI will be calculated from height (m) and weight (kg) and reported in kg/m².

    Time frame: Calculated once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  26. Co-Morbidities

    Participant reported co-morbid medical conditions will be collected and reported as categorical response options and free text.

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  27. Other Medical Diagnoses

    Participant reported medical diagnoses other than asthma will be collected and reported as free text.

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  28. Ethnicity

    Participant reported ethnicity will be collected and reported as categorical options.

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  29. Social Determinants of Health

    Social determinants of health, including factors that may influence health outcomes and healthcare access, will be collected and reported as questionnaire responses.

    Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.

  30. Asthma Control Test (ACT)

    Asthma control will be assessed using the ACT, a validated questionnaire that evaluates asthma symptoms, activity limitations, and overall control. Scores range from 5 to 25, with higher scores indicating better asthma control. The ACT will be used to assess changes in asthma control status throughout study participation.

    Time frame: Measured at screening/baseline prior to the exposure sessions.

  31. Physical Activity Questionnaire for Older Children (PAQ-C)

    The PAQ-C is a self-administered questionnaire that assesses a child's general physical activity level during the previous 7 days. Higher scores indicate greater physical activity.

    Time frame: Measured at baseline prior to the exposures.

  32. Physical Activity Questionnaire for Adolescents (PAQ-A)

    The PAQ-A is a self-administered questionnaire that assesses an adolescent's general physical activity level during the previous 7 days. Higher scores indicate greater physical activity.

    Time frame: Measured at baseline prior to exposures.

  33. Mini Pediatrics Asthma Quality of Life Questionnaire (MiniPAQLQ)

    The miniPAQLQ is a self-administered questionnaire that assess asthma-related quality of life in children, including symptoms, activity limitations and emotional function. Higher scores indicate better quality of life.

    Time frame: Measured at baseline prior to exposures.

  34. International Study of Asthma & Allergies in Childhood (ISAAC) Core Questionnaire for Asthma

    The ISAAC Core Questionnaire for Asthma will be used to assess asthma symptoms and history in control participants to confirm the absence of asthma and other respiratory conditions.

    Time frame: Measured at baseline prior to exposures.

07

Study locations

1 site
  • Ontario Tech University
    Oshawa, Ontario, Canada
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2026
First posted
Oct 7, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07864506
Lead sponsor
University of Ontario Institute of Technology
Responsible party
Mika Nonoyama (Associate professor, University of Ontario Institute of Technology) — Principal investigator
First posted
Oct 7, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Mika L Nonoyama
Contact
mika.nonoyama@ontariotechu.ca
905-721-8668 ext. 5329

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion